First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD StudyEduardo Díaz‐Rubio, Manuel Valladares, Fernando Rivera et al.|The Oncologist|2012Cited by 213
First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD StudyEduardo Díaz‐Rubio, Enrique Aranda, Auxiliadora Gómez‐España et al.|Unknown|2012Cited by 25
PIER trial: Neoadjuvant therapy with panitumumab (P) and mFOLFOX-6 in an enriched population of patients with T3 rectal adenocarcinoma of the middle third with clear mesorectal fascia.Carlos Fernández-Martos, Ruth Vera, Jorge Aparicio et al.|Journal of Clinical Oncology|2018Cited by 0